Sbir phase I: novel self-closing, transcatheter, edge-to-edge repair device to percutaneously treat tricuspid valve regurgitation using jugular or femoral vein access

Ended Project Grant Awarded

Award ID
2322197
Recipient
Awarding agency
Obligated
$275,000

Award facts

Assistance listing
47.084 NSF Technology, Innovation, and Partnerships
Completion date
Place of performance
Newark, CA 94560, USA

Award details come from USAspending.gov.

Description

Abstract
This small business innovation research (SBIR) phase I project develops a novel medical device enabling minimally invasive surgical revision and repair of the tricuspid valve. More than 1.6 million patients in the U.S. Suffer from moderate to severe tricuspid valve regurgitation (TR) resulting in a market-size exceeding $2.4 billion by 2028. The prevalence of this repair increases with age, with women over 4 times more likely to be affected with TR than men. There are no food and drug administration (FDA)-approved percutaneous devices for TR treatment. Isolated TR surgery is rarely performed due to the inherent risks associated with major surgery with post-operative complications resulting in high morbidity and mortality rates of 36.1% among severe TR patients. Hence, only about 8,000 of all U.S. Patients with moderate to severe TR currently receive surgical treatment. This small business innovation research (SBIR) phase I project develops a novel, percutaneous, catheter-based device and procedure for surgically revising the tricuspid valve in patients suffering from tricuspid regurgitation (TR). The tricuspid valve is the largest of the four heart valves presenting unique challenges due to its complex anatomy including 3 thin leaflets and location. The valve is difficult to access using traditional femoral vein access. This project aims to provide a novel, low-profile catheter and implant device via the jugular vein. The phase I objectives include demonstrating the ability to grasp valve leaflets, validating the design using a benchtop model simulating human conditions, further designing, developing and validating an animal model, and performing a transcatheter tricuspid edge-to-edge repair (T-TEER) procedure via the jugular vein in a lab setting. The results from the technology development, bench testing. And preclinical models will further the system towards eventual human use. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.- subawards are not planned for this award.

Quick answers

Who received award 2322197?

2322197 was awarded to Medfree Inc. by National Science Foundation on January 11, 2024.

How much is award 2322197 worth?

$275,000 has been obligated on 2322197.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award